(Total Views: 812)
Posted On: 05/11/2025 6:06:30 AM
Post# of 154730
"As previously announced, CytoDyn is preparing a manuscript summarizing the integrated safety data from the almost 1,600 patients who have already received leronlimab. The final draft of that safety summary will be complete shortly.”
Any idea as to what these anticipated results would mean to the FDA? Would safety still need to be exhibited for every indication in future trials? 1600 is a big number. That's a lot of people who have tolerated LL well. That's not to mention the people who are alive because of it.
Because of ESMO, we are focused on the 12, 24, 36, and 48- month mTNBC survivors. These number were gleaned by the CRO from previous efforts and compassionate use. Might the CRO be able to glean similar numbers for HIV and COVID-19? That seems to be a logical next step. What do you think?
Re-read the Moffet recovery from COVID-19. It is no less astounding today.
Any idea as to what these anticipated results would mean to the FDA? Would safety still need to be exhibited for every indication in future trials? 1600 is a big number. That's a lot of people who have tolerated LL well. That's not to mention the people who are alive because of it.
Because of ESMO, we are focused on the 12, 24, 36, and 48- month mTNBC survivors. These number were gleaned by the CRO from previous efforts and compassionate use. Might the CRO be able to glean similar numbers for HIV and COVID-19? That seems to be a logical next step. What do you think?
Re-read the Moffet recovery from COVID-19. It is no less astounding today.
(17)
(0)
